Karuna Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2020. For the quarter, loss from operations was $24,407,000 against $8,866,000 a year ago. Net loss attributable to common stockholders was $24,009,000 against $7,774,000 a year ago. Net loss per share, basic and diluted was $0.89 against $0.32 a year ago. For the year, loss from operations was $71,816,000 against $45,405,000 a year ago. Net loss attributable to common stockholders was $68,554,000 against $43,957,000 a year ago. Net loss per share, basic and diluted was $2.59 against $3.68 a year ago.